AuntMinnie
MARCH 7, 2024
In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% year over year, according to the newly published IMV 2024 PET Market Summary Report. In 2023, the average number of PET scans per fixed PET site (versus mobile PET) increased 6.7%
AuntMinnie
SEPTEMBER 13, 2023
The Medical Imaging and Technology Alliance (MITA) has raised concerns ove. Read more on AuntMinnie.com Related Reading: ACR urges full coverage for amyloid PET scans CMS proposal covers PET scans for Alzheimer’s disease MITA praises FDA for Leqembi approval FIND Act reintroduced in U.S.
Imaging Technology
JUNE 15, 2023
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Lancet Oncology 2023; 24(3): e133-e143.
AuntMinnie
FEBRUARY 12, 2024
Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. of patients, noted lead author Ke-Liang Chen, MD, a neurologist at Fudan University. “In
AuntMinnie
JANUARY 19, 2024
The promise of imaging One challenge is that advances in Alzheimer’s care can only help people if they are reaching the right patients at the right time in their patient journey. Reimbursement barriers Unfortunately, until recently, there were significant barriers to receiving amyloid PET imaging in some regions.
Imaging Technology
APRIL 28, 2023
Molecular imaging enables doctors and clinicians to see inside the body with a non-invasive process, helping to diagnose and treat diseases such as cancer, cardiovascular disease , and neurological diseases. It can allow early and precise diagnosis.
Imaging Technology
MAY 2, 2023
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.
Expert insights. Personalized for you.
115 
Let's personalize your content